Scotts Miracle-Gro
SMG NYSE Fertilizers & Agricultural Chemicals Financials FY2016βFY2025
Scotts Miracle-Gro's revenue fell 3.9% to $3.4 billion in fiscal 2025. Its operating margin was 10.5%, up from 5.9% a year earlier. Free cash flow was $274 million, down 53.1%. It paid out $173 million in dividends and buybacks, 63% of free cash flow. The diluted share count rose 3.4%.
What Scotts Miracle-Gro does
No business description yet.
- Legal name
- Scotts Miracle-Gro Co
- Fiscal year ends
- September 30, 2025
- Latest annual report
- β
- Accession Β· CIK
- 0000825542-25-000022
0000825542
Revenue and margins
Scotts Miracle-Gro had $3.4B of revenue in fiscal 2025, down 3.9% on the year before.
Net income and earnings per share
From fiscal 2016 to 2025, diluted EPS grew β7.7% a year. Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was $274M in fiscal 2025, 8.0% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Scotts Miracle-Gro returned $173M to shareholders in fiscal 2025, 63% of free cash flow. The diluted share count rose 3.4%.
Value Scotts Miracle-Gro yourself
Change the assumptions and see what they imply per share. These are models, not forecasts or price targets β the answer depends entirely on what you put in.
Discounted cash flow
Value per share
β
Adds net cash of β$2.1B and divides by 58.7M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.
Earnings multiple
Value per share
β
Reference multiples: today 50.2x Β· peers 8.6x Β· sector 20.1x.
Balance sheet
Cash, debt and the ratios that show how comfortably Scotts Miracle-Gro can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $244M | $86.8M | $31.9M | $71.6M | $36.6M |
| Debt incl. finance leases | $2.3B | $3.0B | $2.6B | $2.2B | $2.1B |
| Net debt / EBITDA | 2.5x | β | β | 7.5x | 4.8x |
| Debt / equity | 2.3x | β | β | β | β |
| Interest coverage | 9.2x | β3.7x | β1.0x | 1.3x | 2.8x |
| Current ratio | 1.8x | 2.1x | 1.8x | 1.3x | 1.3x |
| Quick ratio | 0.8x | 0.7x | 0.7x | 0.5x | 0.5x |
| Total assets | $4.8B | $4.3B | $3.4B | $2.9B | $2.7B |
| Total liabilities | $3.8B | $4.1B | $3.7B | $3.3B | $3.1B |
| Shareholders' equity | $1.0B | $148M | β$267M | β$391M | β$358M |
| Net debt (β = net cash) | $2.1B | $2.9B | $2.6B | $2.2B | $2.1B |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
1 insider
Sold, 12 months
$5.5M
3 insiders
Of sales under plans
0%
$0.0M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 10, 2026 | Mark D KingdonDirector | Sold | 831 | $61.65 | $0.1M | Form 4 |
| Aug 3, 2026 | Hagedorn Partnership L.P.Director, 10% owner | Sold | 30,000 | $67.45 | $2.0M | Form 4 |
| Jul 30, 2026 | Stephen L JohnsonDirector | Sold | 1,171 | $68.32 | $0.1M | Form 4 |
| Feb 24, 2026 | Mark J ScheiwerEVP, CFO & CAO | Bought | 693 | $71.44 | $0.0M | Form 4 |
| Feb 12, 2026 | Hagedorn Partnership L.P.Director, 10% owner | Sold | 50,000 | $66.40 | $3.3M | Form 4 |
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | β | β | β |
| Cash from operations is positive | β | β | β |
| Return on assets rose | β | β | β |
| Cash from operations exceeds net income | β | β | β |
| Debt fell relative to assets | β | β | β |
| Current ratio rose | β | β | β |
| Share count didn't rise | β | β | β |
| Gross margin rose | β | β | β |
| Revenue rose relative to assets | β | β | β |
| F-score | 4 / 9 | 5 / 9 | 6 / 9 |
| Accruals ratio | β23.6% | β22.4% | β8.1% |
| Altman Z'' | 1.25 | 1.23 | 1.59 |
Similar companies
Each company's latest fiscal year. Fiscal years end in different months, so periods don't line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score | |
|---|---|---|---|---|---|---|---|---|
| Scotts Miracle-Gro SMG | $3.5B | β3.9% | 10.5% | 8.0% | 13.4% | 50.3x | 6 | |
| FMC FMC | $633M | β18.3% | β47.0% | β3.0% | β19.6% | β | 2 | Compare β |
| CF Industries CF | $18.6B | 19.3% | 32.5% | 25.4% | 20.6% | 9.0x | 8 | Compare β |
| Mosaic MOS | $5.7B | 8.4% | 6.8% | β4.4% | 2.5% | β | 8 | Compare β |
| Corteva CTVA | $8.3B | 2.9% | β | 16.2% | 5.8% | 8.2x | 8 | Compare β |
10 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $2.5B | $2.6B | $2.7B | $3.2B | $4.1B | $4.9B | $3.9B | $3.6B | $3.6B | $3.4B |
| Gross profit | $900M | $973M | $865M | $1.0B | $1.3B | $1.5B | $873M | $657M | $851M | $1.0B |
| Research and development | $36.0M | $39.9M | $42.5M | $39.6M | $39.7M | $45.4M | $45.3M | $35.7M | $34.6M | $34.8M |
| Operating income | $448M | $433M | $199M | $410M | $585M | $723M | β$434M | β$174M | $209M | $359M |
| Interest expense | $62.9M | $76.1M | $86.4M | $102M | $79.6M | $78.9M | $118M | $178M | $159M | $129M |
| Pretax income | $384M | $315M | $116M | $582M | $511M | $677M | β$558M | β$453M | β$23.6M | $222M |
| Income tax | $138M | $117M | β$11.9M | $145M | $124M | $160M | β$121M | β$73.2M | $11.3M | $76.5M |
| Net income | $315M | $218M | $63.7M | $461M | $387M | $513M | β$438M | β$380M | β$34.9M | $145M |
| Diluted EPS | $5.09 | $3.63 | $1.12 | $8.18 | $6.81 | $8.96 | β$7.88 | β$6.79 | β$0.61 | $2.47 |
| Diluted shares | 0.06B | 0.06B | 0.06B | 0.06B | 0.06B | 0.06B | 0.06B | 0.06B | 0.06B | 0.06B |
| Cash flow | ||||||||||
| Cash from operations | $244M | $363M | $343M | $227M | $558M | $272M | β$129M | $531M | $668M | $371M |
| Capital expenditure | $58.3M | $69.6M | $68.2M | $42.4M | $62.7M | $107M | $114M | $92.8M | $84.0M | $97.4M |
| Free cash flow | $186M | $294M | $274M | $184M | $495M | $165M | β$243M | $438M | $584M | $274M |
| Depreciation and amortization | $62.3M | $73.8M | $83.4M | $89.3M | $94.7M | $93.8M | $105M | $92.5M | $80.6M | $75.0M |
| Stock-based compensation | $15.6M | $25.2M | $40.4M | $38.4M | $57.9M | $40.6M | $34.3M | $68.9M | $80.4M | $69.0M |
| Acquisitions | $158M | $122M | $493M | $6.6M | $0.0M | $128M | $237M | $0.0M | $0.0M | $2.5M |
| Share buybacks | $137M | $255M | $328M | $3.1M | $53.2M | $129M | $258M | $9.3M | $5.1M | $18.4M |
| Dividends paid | $117M | $120M | $120M | $125M | $411M | $143M | $166M | $149M | $151M | $154M |
| Dividends and buybacks | $254M | $376M | $448M | $128M | $464M | $272M | $424M | $158M | $156M | $173M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $28.6M | $121M | $33.9M | $18.8M | $16.6M | $244M | $86.8M | $31.9M | $71.6M | $36.6M |
| Total debt | $1.2B | $1.4B | $2.0B | $1.6B | $1.5B | $2.3B | $3.0B | $2.6B | $2.2B | $2.1B |
| Finance lease liabilities | $0.0M | $0.0M | $0.0M | $0.0M | $36.1M | $33.4M | $28.9M | $16.9M | $17.8M | $14.5M |
| Current assets | $1.0B | $882M | $886M | $1.0B | $1.2B | $2.0B | $2.0B | $1.4B | $980M | $940M |
| Current liabilities | $707M | $545M | $613M | $621M | $950M | $1.1B | $964M | $774M | $750M | $740M |
| Inventory | $395M | $408M | $481M | $540M | $622M | $1.1B | $1.3B | $880M | $588M | $593M |
| Property and equipment, net | $445M | $468M | $531M | $546M | $560M | $622M | $606M | $610M | $610M | $632M |
| Total assets | $2.8B | $2.7B | $3.1B | $3.0B | $3.4B | $4.8B | $4.3B | $3.4B | $2.9B | $2.7B |
| Total liabilities | $2.0B | $2.1B | $2.7B | $2.3B | $2.7B | $3.8B | $4.1B | $3.7B | $3.3B | $3.1B |
| Shareholders' equity | $715M | $649M | $355M | $719M | $697M | $1.0B | $148M | β$267M | β$391M | β$358M |
| Margins | ||||||||||
| Gross margin | 35.9% | 36.8% | 32.5% | 32.3% | 32.6% | 29.8% | 22.2% | 18.5% | 23.9% | 30.6% |
| Operating margin | 17.9% | 16.4% | 7.5% | 13.0% | 14.2% | 14.7% | β11.1% | β4.9% | 5.9% | 10.5% |
| EBITDA margin | 20.4% | 19.2% | 10.6% | 15.8% | 16.5% | 16.6% | β8.4% | β2.3% | 8.2% | 12.7% |
| Net margin | 12.6% | 8.3% | 2.4% | 14.6% | 9.4% | 10.4% | β11.2% | β10.7% | β1.0% | 4.3% |
| FCF margin | 7.4% | 11.1% | 10.3% | 5.8% | 12.0% | 3.3% | β6.2% | 12.3% | 16.4% | 8.0% |
| Returns | ||||||||||
| Return on capital | 15.7% | 14.1% | 9.3% | 13.1% | 19.5% | 20.8% | β11.2% | β5.1% | 8.0% | 13.4% |
| Return on capital employed | 22.6% | 20.4% | 8.6% | 16.9% | 24.2% | 23.8% | β12.4% | β5.8% | 8.8% | 17.4% |
| Return on equity | 47.2% | 32.0% | 12.7% | 85.9% | 54.7% | 59.9% | β75.4% | β | β | β |
| Return on assets | 11.9% | 7.9% | 2.2% | 15.2% | 12.1% | 12.5% | β9.6% | β9.9% | β1.1% | 5.2% |
| Growth | ||||||||||
| Revenue growth | β16.9% | 5.4% | 0.8% | 18.5% | 30.9% | 19.2% | β20.3% | β9.5% | 0.0% | β3.9% |
| Net income growth | 97.3% | β30.8% | β70.8% | 623.2% | β15.9% | 32.3% | β185.4% | β | β | β |
| EPS growth | 98.1% | β28.7% | β69.2% | 630.4% | β16.8% | 31.6% | β188.0% | β | β | β |
| FCF growth | 0.3% | 58.1% | β6.6% | β32.8% | 168.6% | β66.8% | β247.3% | β | 33.2% | β53.1% |
| Share count change | β0.3% | β2.9% | β5.2% | β1.4% | 1.1% | 0.5% | β3.0% | 0.9% | 1.4% | 3.4% |
| Financial health | ||||||||||
| Net debt / EBITDA | 2.3x | 2.5x | 7.1x | 3.2x | 2.2x | 2.5x | β | β | 7.5x | 4.8x |
| Debt / equity | 1.7x | 2.2x | 5.7x | 2.3x | 2.2x | 2.3x | β | β | β | β |
| Interest coverage | 7.1x | 5.7x | 2.3x | 4.0x | 7.4x | 9.2x | β3.7x | β1.0x | 1.3x | 2.8x |
| Current ratio | 1.5x | 1.6x | 1.5x | 1.7x | 1.3x | 1.8x | 2.1x | 1.8x | 1.3x | 1.3x |
| Quick ratio | 0.9x | 0.9x | 0.7x | 0.8x | 0.6x | 0.8x | 0.7x | 0.7x | 0.5x | 0.5x |
| Capital allocation | ||||||||||
| Capex / revenue | 2.3% | 2.6% | 2.6% | 1.3% | 1.5% | 2.2% | 2.9% | 2.6% | 2.4% | 2.9% |
| Stock comp / revenue | 0.6% | 1.0% | 1.5% | 1.2% | 1.4% | 0.8% | 0.9% | 1.9% | 2.3% | 2.0% |
| Payouts / FCF | 136.8% | 127.9% | 163.2% | 69.2% | 93.8% | 165.4% | β | 36.2% | 26.8% | 63.1% |
| Quality scores | ||||||||||
| Piotroski F-score | 6.0 | 6.0 | 5.0 | 7.0 | 6.0 | 5.0 | 3.0 | 4.0 | 5.0 | 6.0 |
| Altman Z'' | 3.3 | 3.4 | 2.2 | 3.5 | 3.2 | 3.6 | 1.7 | 1.3 | 1.2 | 1.6 |
| Accruals ratio | 2.7% | β5.3% | β9.6% | 7.7% | β5.3% | 5.9% | β6.8% | β23.6% | β22.4% | β8.1% |
Source: SEC EDGAR XBRL filings (CIK 0000825542). Data updated October 14, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.